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Abstract
MeDALL (Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No:
261357; 2010–2015) has proposed an innovative approach to develop early indicators for
the prediction, diagnosis, prevention and targets for therapy. MeDALL has linked epi-
demiological, clinical and basic research using a stepwise, large-scale and integrative
approach: MeDALL data of precisely phenotyped children followed in 14 birth cohorts
spread across Europe were combined with systems biology (omics, IgE measurement using
microarrays) and environmental data. Multimorbidity in the same child is more common
than expected by chance alone, suggesting that these diseases share causal mechanisms
irrespective of IgE sensitization. IgE sensitization should be considered differently in
monosensitized and polysensitized individuals. Allergic multimorbidities and IgE polysen-
sitization are often associated with the persistence or severity of allergic diseases. Environ-
mental exposures are relevant for the development of allergy-related diseases. To
complement the population-based studies in children, MeDALL included mechanistic
experimental animal studies and in vitro studies in humans. The integration of multimor-
bidities and polysensitization has resulted in a new classification framework of allergic dis-
eases that could help to improve the understanding of genetic and epigenetic mechanisms
of allergy as well as to better manage allergic diseases. Ethics and gender were considered.
MeDALL has deployed translational activities within the EU agenda.
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AD, atopic dermatitis; AIRWAYS ICPs, Integrated care pathways for airway diseases (EIP on AHA); AMIC, Asthma Multicentre Infant Cohort
Study; BAMSE, Barn Allergi Milj. Stockholm Epidemiologi Projektet; BIB, Born in Bradford; CC16, club cell secretory protein; CQ, Core
Questionnaire; DARC, Danish Allergy Research Centre; ECA, Environment and Childhood Asthma; ECRHS, European Community
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Allergic diseases such as asthma, rhinitis and eczema are
complex and are associated with allergen-specific IgE and
nonallergic mechanisms (1). They often coexist in the same
subject (multimorbidity) (2) and are multifactorial, with
genetic, lifestyle and environmental components. These inter-
actions start early in life, develop during infancy and child-
hood (3) and may persist throughout life.
Allergic diseases are not separate diseases, but are linked
by complex and insufficiently defined interrelationships across
the life cycle. There is a growing interest to apply the systems
approach proposed in systems biology to complex chronic
diseases (4). The 7th Framework Programme of the EU pro-
moted research to develop systems medicine in order to
better understand chronic diseases. MeDALL (Mechanisms
of the Development of ALLergy; EU FP7-CP-IP; Project
No: 261357; 2010–2015) has attempted to better understand
the complex links of allergic diseases at the clinical and
mechanistic levels (1, 5).
MeDALL completed its project in May 2015, and the pre-
sent paper reports the results and achievements published by
the consortium to date.
Innovative approach
MeDALL was one of the first EU projects to adopt a sys-
tems medicine approach for the understanding of complex
NCDs (1, 5). It has generated novel knowledge on the mech-
anisms of initiation of allergy from early childhood to young
adulthood. MeDALL has linked epidemiological, clinical and
basic research (6). It was based on a novel, stepwise, large-
scale and integrative approach led by a network of all neces-
sary experts. The following steps were proposed and devel-
oped during the project:
1. Identification of ‘classical’ and ‘novel’ phenotypes in
existing birth cohorts (Table 1).
2. Discovery of the relevant mechanisms in IgE-associated
allergic diseases in existing longitudinal birth cohorts.
3. Validation and redefinition of the classical and novel
phenotypes of IgE-associated allergic diseases.
4. Translational integration of systems biology outcomes
into health care, including societal aspects.
The strategy of MeDALL was based on information and
samples (already existing in the repository and acquired dur-
ing the project) obtained from a large network of 14 ongoing
birth cohorts.
Major methodological achievements
Development of a knowledge management platform
Systems medicine involves the large-scale integration of
existing knowledge with newly acquired multidimensional
data. The MeDALL knowledge management platform was
developed to empower all partners with open sharing and
access to all the data and information collected, as well as
to all the experimental and computational procedures. The
MeDALL knowledge base integrates historical and newly
collected data from around 44 000 participants on 398
clinical and phenotypic attributes (harmonized from 7495
individual cohort variables) and 160 different follow-ups at
25 different time points between pregnancy and age 20. It
also contains information about available blood samples
that are stored in the individual biobanks of the different
MeDALL partners.
Information on 863 genes involved in allergy (283 from a
systematic literature review and 580 from automatic text min-
ing) is integrated with data on protein–protein interactions,
transcriptional regulation, miRNA regulation and signalling
pathways from public databases. It is directly connected to
the omics data generated within MeDALL.
Omics data produced or made available within MeDALL
include 23 000 historical GWAS, 9500 epigenetics, 2000 pro-
teomics, 750 transcriptomics, IgE microarrays (4000 subjects)
and individual estimates of ambient air pollution exposure
(10 000 children) using the land use model (ESCAPE) (7–10).
The newly performed epigenetics, proteomics, transcrip-
tomics and IgE microarray data are integrated into the
MeDALL knowledge base which currently includes 3292 IgE
chips, 2173 DNA methylations, 1427 biomarkers and 723
transcription experiments. The availability of longitudinal
samples of the same individual is a unique resource.
Development of the harmonized MeDALL-Core
Questionnaire (in eight languages) (11)
Numerous birth cohorts have been initiated throughout the
world using heterogeneous methods to assess the incidence,
course and risk factors for asthma and allergies (12). One of
the major achievements of MeDALL was the development of
the harmonized MeDALL-Core Questionnaire (MeDALL-
CQ), used historically in 14 cohorts and prospectively in 11
(11). The harmonization of standardized core questions was
accomplished in four steps: (i) collection of previous ques-
tions from 14 European birth cohorts, (ii) consensus on core
questionnaire items, (iii) translation and back-translation of
the harmonized English MeDALL-CQ into eight languages
and (iv) implementation of the three core questionnaires
MeDALL-CQ (two for parents of children aged 4–9 and 14–
18 and one for adolescents aged 14–18). The harmonized
MeDALL follow-up leads to more comparable data across
different cohorts and offers the possibility to validate the
results of former single cohort analyses.
Worldwide interest has been expressed in the MeDALL-
CQs: future follow-up assessments of the Cincinnati Child-
Table 1 MeDALL dual approach
Hypothesis-driven approach: The identification of classical
phenotypes was based on experts’ criteria following a review of
the literature aiming at the definition of IgE-associated allergic
diseases.
Data-driven approach: To identify the novel phenotypes, the
children from the birth cohorts were analysed using hypothesis-
free methods by cluster analysis.
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hood Allergy and Air Pollution Study (CCAAPS) birth
cohort (13) and of the large Japanese national birth cohort
Japan Environment and Children’s Study (JECS), which
recently recruited 100 000 parent–child pairs (www.env.go.jp/
en/chemi/hs/jecs/).
Development of a database of pooled cohorts using a
harmonized questionnaire (12)
MeDALL birth cohorts include AMICS-Menorca**
(14), BAMSE** (15), BIB* (16, 17), DARC** (18), ECA**
(19), EDEN* (20), GINI plus** (21, 22), INMA*
Gipuzkoa, Sabadell, Valencia (23), LISA plus** (24), MAS
(25–28), PARIS* (29), PIAMA (30), RHEA*(31) and
ROBIC* (32).
MeDALL included the birth cohorts with historical
databases and harmonized follow-up (11). They were inte-
grated in a knowledge management system (33) (Table 2).
A joint NIH-MeDALL workshop on birth cohorts in allergy
and asthma was organized in September 2012 to address a
wide research agenda, including potential new study designs
and the harmonization of existing birth cohort data (6).
The MeDALL database with its new central database is
the starting point for future common and sustainable
research initiatives in asthma and allergy. It can be extended
with other epidemiologic studies such as birth and patient
cohorts.
Development of a new allergen microarray technology
The ‘MeDALL allergen-chip’ is a collection of 170 allergen
molecules for the reliable detection of allergen-specific anti-
body signatures. When compared to the traditional Immu-
noCAP, this system shows a higher sensitivity. The new tool
has been integrated in clinical work within MeDALL and
beyond, allowing a hitherto not available precision regarding
the mapping of sensitization profiles down to the level of dis-
ease-causing allergens and the monitoring of the early evolu-
tion of the allergic immune response (34–37). The MeDALL
allergen-chip is a customized chip by ThermoFisher, which
includes a large collection of allergens produced by the
MeDALL consortium.
Applying bioinformatics to develop the systems medicine
approach
The working hypothesis underlying systems medicine
approaches is that biological function and dysfunction in dis-
ease develop from the interplay between spatial and temporal
processes involving multiple components interacting in com-
plex networks. The ultimate goal of systems medicine is
therefore to understand, as fully as possible, this integrative
process and to identify directions to investigate the develop-
ment of more efficient clinical diagnostics and therapies. In
MeDALL, we have integrated bioinformatics with more tra-
ditional methods (classical and novel phenotypes). We have
used machine-learning methods as an unsupervised strategy
to identify novel phenotypes and have developed an in silico
model of multimorbidity.
Applying machine-learning methods to identify novel pheno-
types
In MeDALL, we used an unsupervised approach to identify
novel phenotypes. At variance with previous studies that
applied this method to one single disease, we assessed
asthma, rhinitis and eczema together in the same models (5).
We included 17 209 children at 4 years and 14 585 at 8 years
from seven birth cohorts. At each age period, we performed
partitioning cluster analysis, according to the distribution of
23 variables covering: symptoms ‘ever’ and ‘in the last
12 months’; doctor diagnosis; age of onset and treatments
for asthma, rhinitis and eczema; IgE sensitization; weight;
and height. The analysis used repeated latent class analysis
and self-organizing maps.
Development of a bioinformatic model of multimorbidity of
allergic diseases
An in silico study based on the analysis of the topology of
the protein interaction network was performed to character-
ize the molecular mechanisms of multimorbidity of asthma,
Table 2 Pooled MeDALL database
 AMICS-M: data from 482 integrated participants with up to 12
follow-ups.
 BAMSE: data from 4089 integrated participants with up to five
follow-ups.
 BiB: data from 13 565 (2594 in MeDALL) integrated participants
with up to seven follow-ups.
 DARC: data from 562 integrated participants with up to nine
follow-ups.
 ECA: data from 3754 integrated participants with up to six
follow-ups.
 EDEN: data from 1140 integrated participants with up to six
follow-ups.
 GINI: data from 5991 integrated participants with up to eight
follow-ups.
 LISA: data from 3095 integrated participants with up to nine
follow-ups.
 INMA-Gipuzkoa: data from 406 integrated participants with up to
four follow-ups.
 INMA-Sabadell: data from 772 integrated participants with up to
seven follow-ups.
 INMA-Valencia: data from 855 integrated participants with up to
six follow-ups.
 MAS: data from 1314 integrated participants with up to 19
follow-ups.
 PARIS: data from 1549 integrated participants with up to 10
follow-ups.
 PIAMA: data from 3963 integrated participants with up to 12
follow-ups.
 RHEA: data from 1336 integrated participants with up to six
follow-ups.
 ROBBIC-Bologna: data from 434 integrated participants with up
to five follow-ups.
 ROBBIC-Roma: data from 694 integrated participants with up to
six follow-ups.
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eczema and rhinitis. As a first step, proteins associated with
either disease were identified using data mining approaches,
and their overlap was calculated. Secondly, the functional
interaction network was built, allowing the identification of
cellular pathways involved in allergic multimorbidity. Finally,
a network-based algorithm generated a ranked list of newly
predicted multimorbidity-associated proteins (Aguilar, sub-
mitted).
Novel findings
Literature review on phenotypes and course of allergic
diseases in children
A large heterogeneity of allergic phenotypes exists and no sys-
tematic review had been carried out on phenotype classifica-
tion or multimorbidity. MEDLINE was searched up to
December 2012 to identify relevant original studies in children.
From a total of 13 767 citations, 197 met the criteria for inclu-
sion, of which 54% were cohorts. The review showed that
studies reporting the phenotypes of IgE-associated diseases in
children are heterogeneous and often lack objective measures.
The knowledge on multimorbidity was mostly restricted to
links between asthma and rhinitis (38).
Classical and novel phenotypes reveal the importance of
multimorbidity
The term ‘multimorbidity’ is more appropriate than comor-
bidity because the primary allergic disease is poorly known
and the allergy march accounts for few patients (39).
Although the concept of multimorbidity of allergic diseases
has been known for years (40), MeDALL is the first popula-
tion study to have assessed allergic multimorbidity of allergic
diseases using the dual approach: hypothesis driven (41) and
data driven (unsupervised cluster analyses) (42). It is also the
first to have quantified the net excess of multimorbidity (41).
Classical epidemiological methods enabled a precise
analysis of the multimorbidity of asthma, rhinitis and eczema
(41). The absolute excess of any multimorbidity was 1.6%
for children aged 4 and 2.2% for children aged 8. 44% of
the observed multimorbidity at the age of 4 and 50.0% at
the age of 8 were not a result of chance. Children with
multimorbidities at 4 years had an increased risk of having
multimorbidity at 8 years. The coexistence of eczema, rhinitis
and asthma in the same child is more common than expected
by chance alone, suggesting that these diseases share causal
mechanisms. For children without multimorbidity at 4 years,
38% of the multimorbidity at the age of 8 was attributable
to the presence of IgE sensitization at the age of 4. On the
other hand, the use of machine-learning methods (42) showed
that 30 to 40% of children at the age of 4 to 8 belong to a
multimorbidity cluster. This cluster included 99% of children
exhibiting multimorbidity with classical models. Although
IgE sensitization is independently associated with excess mul-
timorbidity, its presence at 4 years accounted for only 38%
of the new multimorbidity at the age of 8, suggesting that
IgE sensitization can no longer be considered the common
causal mechanism of multimorbidity for these diseases
(Fig. 1).
Monosensitization and polysensitization of distinct allergy
phenotypes
The concept of monosensitization and polysensitization has
been previously proposed (43–45), but never formally evalu-
ated due to the lack of samples in a population-based study
and inadequate methods, making it impossible to study a
wide array of allergens. This became possible in MeDALL.
In the BAMSE cohort (Sweden), the same 2607 children were
tested at least twice at 4, 8 and 16 years (46). Results confirm
that monosensitization and polysensitization represent two
different phenotypes of IgE-associated diseases. These results
were also confirmed in the MeDALL cohorts (2) and in
patient cohorts in children (47). In the EGEA study, the
monosensitized and polysensitized MeDALL phenotypes (2)
were confirmed in adults (48).
Effect of pollutants in the development of allergic diseases
Traffic-related air pollution (nitrogen dioxide (NO2), particu-
late matter < 2.5 lm (PM2.5), < 10 lm (PM10) and PM2.5
absorbance (‘soot’)) was studied. In four cohorts, residential
exposure to traffic-related air pollution at the birth address
and follow-up addresses was examined (10, 49, 50). Exposure
to nitrogen dioxide (NO2) and PM2.5 absorbance early in
life is a risk factor for the development of asthma through
childhood and adolescence, particularly after the age of 4
(49). Analyses of other environmental risk factors for allergy-
related disease (e.g. second-hand tobacco smoke, moulds,
dampness) are ongoing.
Gender switch during puberty
Longitudinal gender-specific analyses of 18 852 children par-
ticipating in PIAMA, BAMSE, LISAplus, GINIplus, DARC
and MAS showed considerable changes in the sex-specific
occurrence of asthma and allergic rhinitis at around puberty.
The strong male predominance of asthma or rhinitis preva-
lence in prepubertal childhood declined as the teenagers grew
older (manuscripts in preparation). Our hypothesis that by
adulthood the gender imbalance in the prevalence is switch-
ing to a clear female predominance of asthma and rhinitis
will be examined with the next follow-up data of MeDALL
cohorts in adulthood.
Omic data for allergy molecular fingerprints and phenotype
handprints
In the discovery phase of targeted proteomics, levels of a
large panel of proteins via multiplexing and ELISAs were
measured in four cohorts. In the replication phase, top
biomarkers of interest were measured in seven cohorts. The
analyses identified a potential novel biomarker of asthma
and the role of systemic inflammation in multimorbidities in
early childhood. Results were consistent using the classical
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and novel phenotypes (manuscript in preparation). Follow-
ing a hypothesis-driven approach, MeDALL data for CC16
(club cell secretory protein) were included in a large interna-
tional collaborative study. Low CC16 levels at the age of 4
predicted subsequent FEV1 deficits up to the age of 16 in
the BAMSE cohort, and these data were in line with inde-
pendent results from the CRS (USA) and MAAS (UK)
cohorts (50).
An epigenome-wide association study on asthma was com-
pleted and followed up by a large replication study across all
MeDALL cohorts (Xu et al., 2016, in preparation). Based on
an a priory hypothesis, strong and consistent effects of mater-
nal smoking on the child’s whole-blood DNA methylome at
the of age 0, 4/5 and 8 were observed and the results pub-
lished as part of the PACE consortium (Joubert et al., sub-
mitted). Moreover, the effects of traffic-related air pollution
on DNA methylation have been investigated (Gruzieva et al.,
2016, in preparation).
Expression profiling of the identified genes is currently
ongoing in these projects, based on the transcriptomic profil-
ing elaborated at single- and multicohort levels, for single
disease phenotypes and multimorbidities. An exhaustive port-
folio of significant and statistically validated genes, molecular
interactions and pathways is available. A set of overlapping
genes defines molecular fingerprints related to asthma, rhini-
tis and eczema, blood cell activity, immune and antigen
response and receptor activity (Lemonnier et al., in prepara-
tion). Integrative analyses of large-scale transcriptomics and
epigenomics datasets with protein expression levels enabled
the discovery of an initial allergy phenotype handprint (Bal-
lereau et al., in preparation).
In comprehensive integrative analyses, protein levels were
analysed in relation to both genetic variation and methyla-
tion profiles in their encoding genes. Multiple CpG sites from
25 genes were found for possible mediation of effects of
genetic variation on protein levels. By identifying a set of
putatively functional SNPs and CpG methylation sites, these
results may provide specific loci to be investigated in associa-
tion studies. A focused integrated analysis in childhood
asthma was completed with genetic–epigenetic–protein data
for the asthma biomarker chitinase-3-like protein 1 (CHI3L1/
YKL-40. It showed that CHI3L1 genetic variation affects cir-
culating YKL-40 by regulating its gene methylation profiles
(Guerra S et al., in preparation).
Mechanistic experimental studies in animal studies and
in vitro to complement MeDALL data
A major achievement has been the construction of transgenic
mice in which the TCR reacts to the relevant Der p 1 aller-
gen of house dust mite (HDM). A fine mapping of the T-cell
response to HDM in vivo was possible. This was achieved by
performing the microarray analysis of CD4 T cells obtained
from these TCR transgenic mice, essentially unravelling a
4 years                                                  8 years
Group 1                Group 2                      Group 1                      Group 2          
n = 12502 (70%)      n = 5157 (30%)          n = 11456 (79%)       n = 3129 (21%)
Wheezing ever
Wheezing attacks last 12 months
Wheezing after exercise ever
Asthma ever
Asthma treatment last 12 months
Asthma onset before 2 years
Bronchitis/bronchiolitis ever
Cough at night ever
Sneezing or blocked nose ever
Sneezing or blocked nose last 12 months
Itchy watery eyes last 12 months
Allergic rhinitis ever
Rhinitis onset before 2 years
Itchy rash ever
Itchy rash last 12 months
Itchy rash affecting common areas
Itchy rash onset before 2 years
Eczema ever
Urticaria ever
Food allergy ever
Positive to specific IgE
Figure 1 Prevalence* of symptoms of asthma, rhinitis and eczema according to the two groups identified in cluster analysis, at 4 and
8 years (Garcia-Aymerich et al. (42)).
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novel IL-21-producing T-cell subset involved in asthma
development (51). We also validated the effect of farm expo-
sure on the development of allergy and asthma. Mice
exposed to farm dust fail to mount allergy and asthma to
HDM due to a downregulation of epithelial cell activation
and a subsequent lack of dendritic cell activation. The path-
way involved the ubiquitin-modifying enzyme A20. Genetic
polymorphisms of A20 were associated with the risk of
developing asthma in a cohort study of children in rural
Germany (52). The latter study also involved innovative air–
liquid interface cultures of epithelial cells obtained by
bronchoscopy. In air–liquid interface cultures of asthmatics,
A20 levels were reduced compared with healthy controls.
In allergic patients, the immune profile of the tonsils repre-
sents the atopic status of patients, with low expression of
Th1. Cellular and molecular mechanisms of tolerance induc-
tion to food and aeroallergens occur in human tonsils,
suggesting that they represent a suitable lymphatic organ for
direct immune interventions (53–55). In addition to Treg
cells, IL-10-producing regulatory B cells have been demon-
strated with a potent anti-inflammatory activity.
Cytokine-producing memory B-cell subsets exist in humans
and may show different pro-inflammatory, anti-inflammatory
as well as immune effector and immune regulatory functions.
We identified novel molecules that play a role in B-cell regu-
lation and demonstrate that functional human B-cell subsets
show in vivo clonal expansion during allergen tolerance, such
as allergen immunotherapy and high-dose allergen exposure
(56, 57). Moreover, Treg cells are reduced during asthma
exacerbations as markers of virus-induced asthma exacerba-
tions, which are of great interest for the development of
future biomarkers (58). To better analyse cytokine-producing
immune cell subsets, we developed an assay that allows the
purification of any single and several cytokine-secreting cell
subsets as well as their characterization (59).
The bronchial epithelial layer serves as the first site of
exposure to inhaled allergens, dust particles, pollutants or
microorganisms. Consequently, bronchial epithelial cells are
at the forefront of tissue defense and the innate immune
response, preventing the invasion of tissues as a physical bar-
rier. Tight junctions (TJs), located at the most apical region
of the lateral cell membrane, seal the epithelium and form an
essential part of the barrier between inner tissues and the
external environment. They can be regulated by cytokines of
the allergy pathways (60, 61). Many efforts have been made
to improve the barrier integrity, and it was recently demon-
strated in vitro that the administration of CpG-DNA could
be useful for restoring impaired epithelial barriers (62).
Novel classification of allergic diseases: the MeDALL
hypothesis (2)
IgE sensitization should be considered as a qualitative (IgE
response) and quantitative trait (monosensitization and
polysensitization), as important clinical and immunological
differences exist between monosensitized and polysensitized
subjects (Table 3). The integration of multimorbidities and
polysensitization has resulted in a new classification frame-
work of allergic diseases (2, 47), which could help to improve
the understanding of genetic and epigenetic mechanisms of
allergy and better manage allergic diseases (Tables 4 and 5).
Clinical impact
Many MeDALL data have been translated into clinical
practice, and a meeting at the European Parliament was
organized by EFA (European Federation of Allergy and
Airways Diseases Patients’ Association) to conclude the
project (27 May 2015). In particular, MeDALL results
have an impact on precision medicine as they improve the
stratification of allergic preschool children for diagnosis,
prognosis and allergen-specific immunotherapy. Multimor-
bidity and IgE polysensitization are markers of persistence
of disease.
Childhood asthma prediction models
Early identification of children at risk of developing asthma
at school age is crucial, but the usefulness of childhood
asthma prediction models in clinical practice is still unclear.
Table 3 Differences between monosensitized and polysensitized
subjects
Polysensitization, as compared to nonsensitization and
monosensitization, is associated with (2):
 A higher frequency of family history of allergy (asthma and
rhinitis) (92).
 A higher prevalence of asthma and rhinitis symptoms.
 A higher prevalence of multimorbidity.
 A higher level of specific IgE and a higher level of total IgE
compared to monosensitized.
 A broader sensitization to different allergens.
 The persistence of allergic diseases with a lower probability of
remission of IgE sensitization and clinical allergy.
Table 4 Novel classification of IgE-mediated diseases (2)
1. Nonsensitized asymptomatic individuals.
2. IgE response restricted to one environmental allergen with no
family history: low IgE responders (the number of components
and level of IgE).
 Nonsymptomatic subjects who are unlikely to develop symptoms
over time.
 Symptomatic subjects (symptoms similar to polysensitized
subjects).
3. Polyclonal IgE response to environmental allergens with family
history: high IgE responders: Most subjects are symptomatic,
with an early life onset, a high rate of multimorbidities and
persistence of the disease over time.
4. Nonallergic polyclonal IgE without family history: late-onset
disease and local polyclonal IgE.
5. Intermediate phenotypes.
 Polyclonal IgE response without family history. The role of
cofactors (pollutants, viruses) needs to be better understood.
 IgE response restricted to few allergens.
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We systematically reviewed all existing prediction models to
identify preschool children with asthma-like symptoms at risk
of developing asthma at school age. Some models were able
to better predict asthma development and others to better
rule it out. However, the predictive performance in both
aspects simultaneously stood out in neither of the models.
This study suggests that the prediction of asthma develop-
ment is difficult (63), possibly because of interactions with
viral infections.
Prediction of the persistence of allergic diseases at 4 years
Polysensitization and/or multimorbidity at 4 years predicts
the persistence of allergy later in life (36, 37, 41). This result
is of importance for the parents of affected children. ‘Will
my child grow out of his or her allergy?’ is the invariable
question raised by the parents. Polysensitization to the major
birch pollen allergen in combination with allergens of the
same protein family predicted future birch pollen allergy
much better than IgE to the birch pollen allergen extract
itself. The same was true for polysensitization to different cat
and dog allergens in relation to the development of cat and
dog allergy, respectively. The MeDALL results are the first
that may propose a simple answer to the practising physician
if the results are confirmed elsewhere.
Stratification of patients for the initiation of allergen-specific
immunotherapy
The results of the MeDALL (monosensitization–polysensiti-
zation, multimorbidity) study, the systematic review on pre-
diction models as well as recent studies in patients with
allergic rhinitis (64) and in the EGEA cohort (48) may help
to propose a stratification of patients for treatment and
future randomized control trials (65). Moreover, the molecu-
lar sensitization profiles determined with the MeDALL chip
may be the basis for the stratification for allergen-specific
immunotherapy (65).
Patient empowerment
The goal and rationale of patient involvement in medical
decisions is patient empowerment. Empowered patients know
their disease. Since its inception, MeDALL has worked for
and with patients for their empowerment in the project.
EFA, one of the MeDALL partners, was present at the
beginning and end of the project.
Ethics
A specific WP was dedicated to ethics in MeDALL to man-
age ethical issues throughout the project. In addition, the
ethics WP prepared practical information on regulatory
issues for exchanging biological samples and attached data
for the relevant partners of MeDALL. This was made avail-
able as a practical web-based tool, as a complementary devel-
opment of the site hSERN.eu developed by GA²LEN (66,
67). The conditions for exchanges of samples and data
regarding a few countries (www.hsern.eu) were integrated
online on the hSERN website. The communication of results
and disclosure of incidental findings in longitudinal paediatric
research have been innovative MeDALL initiatives (68).
Table 5 Implications of the novel definition of IgE-associated allergic diseases (2)
Subphenotyping of allergic diseases for precision medicine: Phenotyping subtypes can be used to characterize allergic diseases, severity
and progression and may help identify unique targets for prevention and treatment.
Clinical practice: An updated definition provides a framework to inform decisions relating to treatment priorities and to indicate need for
improvement in health care and delivery through better organization for prediction, diagnosis and treatment. The prediction of allergic
disease trajectories in preschool children is essential.
Clinical trials: Clarity on definitions is essential for clinical trials, evaluating efficacy and safety. The stratification of patients by sensitization
and multimorbidity is essential in allergen immunotherapy (both for treatment and for prevention).
Research on mechanisms and genetics: The new definition is likely to change the concepts of the mechanisms of allergic disease and to
propose novel mechanisms related to shared and unique genetic factors (93–95).
Population studies: In longitudinal epidemiological population studies, standardized definitions are required to be able to compare cohorts
across time and place and to develop dynamic models capturing risk factors that predict transitions through different stages of health.
Public health planning: For public health purposes, a comprehensive definition is needed (i) to identify the prevalence, burden and costs incurred
by all phenotypes, (ii) to improve quality of care and optimize healthcare planning and policies and (iii) to model the economic and social benefits
of population-level preventive policies to improve respiratory health of the current generation of children and thus of future generations.
Social welfare planning: For social welfare purposes, a phenotypic definition is also needed to predict the burden and costs at an early age
in order to model the individual and collective economic and social benefits of specific interventions.
Applicability to high- and low-income countries: A uniform allergy definition should be applicable to the local and geographical conditions of
all countries, phenotypes, risk factors, availability and affordability to treatment differing widely around the world. This would help to better
understand which preventive measures are most effective in specific environments and interactions with parasitic diseases in particular.
Development of novel preventive approaches and therapies: Detailed cellular and molecular phenotyping is needed to identify novel primary
and secondary prevention strategies, as well as new targets for the development of novel therapies. Ultimately, novel therapies studied in
clinical trials should help define IgE-mediated pathways and determine the importance of the intervention in large patient populations or in
subpopulations of patients based on the concept of distinct phenotypes. The life course approach of allergic diseases is of great interest
because it may lead to preventive strategies for health promotion and preventive policy measures.
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MeDALL at the cross-roads of the EU and WHO
political agenda
European Innovation Partnership on Active and Healthy
Ageing (EIP on AHA) and WHO
The NCD WHO research agenda indicated that birth cohorts
were needed for the understanding of the early determinants
of chronic respiratory diseases for innovative health promo-
tion strategies (69). MeDALL is in line with this agenda.
The WHO Global Alliance against Chronic Respiratory
Diseases (GARD) action plan (70–72) was the model of
AIRWAYS ICPs (integrated care pathways for airway dis-
eases) (73–75), a new initiative of the EIP on AHA. This was
jointly organized by MeDALL, the Reference Site Network
of the EIP on AHA (DG Sante and DG Connect) (76) and
WHO GARD (Fig.2).
MeDALL has interacted with the EIP on AHA (76–78)
via several actions. Synergies have been achieved between
MeDALL and AIRWAYS ICPs – the model of chronic dis-
eases of Area 5 of the B3 Action Plan of the EIP on AHA
(73) – due to their burden, mortality and comorbidities (71)
as well as their early development (79, 80). AIRWAYS ICPs
has strategic relevance to the European Union Health Strat-
egy, adding value to existing public health knowledge.
Impact of MeDALL on the EU policies in the early diagnosis
and management of allergic diseases in active and healthy
ageing
The leading priority for the Polish Presidency of the Council
of the European Union (2011) was to reduce health inequali-
ties across European societies and, within its framework, to
concentrate on the prevention and control of respiratory dis-
eases in children in order to promote AHA (79, 80). The
clinical implications of MeDALL reinforce the priority of
the EU and suggest solutions for implementation.
Pre- and perinatal events play a fundamental role in health,
the development of diseases and ageing (79, 80). The develop-
mental determinants of NCDs in ageing were reinforced dur-
ing the Cyprus Presidency of the EU Council (2012) (81). A
meeting was convened by the Reference Site of Languedoc
Roussillon (76) on the early determinants of active and
healthy ageing (NIH, EIP on AHA, MeDALL) (82). These
concepts have been considered in the senioral policy of
Poland (83). Moreover, the project results were presented on
the 28th of May 2015 at the European Parliament in Brussels
to an audience composed of policy makers, healthcare profes-
sionals, researchers and patients’ representatives.
Translation into policies
The first results of ‘The Finnish Allergy Programme 2008–
2018’ (84), supported by MeDALL data, indicate that allergy
burden can be reduced with relatively simple means. This has
been endorsed by the Norwegian Allergy Health Programme
and, along with the Finnish programme, will serve as a
platform for other countries (Oslo, November 2014) (85).
Gaps and the future
The European Commission considers MeDALL to be a suc-
cess story. A summary can be found on the Horizon 2020
website. It will also be present in the future Health Success
Stories Brochure, scheduled to be launched within the next
few months.
As other similar projects, MeDALL has involved a huge
multidisciplinary effort by a large international network of
partners. MeDALL has been made possible thanks to previ-
ous consortiums (such as GA2LEN, ENRIECO and CHI-
COS) (12) that have paved the way of pooling and
integrating national or local birth cohorts. Each of these con-
sortiums has experienced the challenge of sustaining the net-
work. MeDALL includes over 44 000 children recruited at
birth for the study of the most common chronic disease (al-
lergy). The power of the study is sufficient for the assessment
of primary diseases (asthma, rhinitis and eczema), but it is at
the limit for multimorbidity, in particular at the early stages
of the disease (4 years) (41) and for the discovery of
EIP on AHA
Acon Plan B3
GINA GOLDARIAEFA
AIRWAYS ICPs
DG Santé
DG CONNECT
DG Research
MeDALL WP10
EIP on AHA Reference Site
WHO priorized agenda
On NCD researchGARD
1990-2004
2004-
2010-
2013-
Figure 2 MeDALL interactions between EU and WHO (from Ref.
(74)). GARD, Global Alliance against Chronic Respiratory Diseases;
NGO, nongovernmental organization; GO, governmental organiza-
tion; MOH, Ministry of Health; NCD, noncommunicable disease.
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biomarkers. In studies of multimorbid NCDs (e.g. COPD,
cardiovascular diseases, diabetes), the power of population
cohorts will be sufficient to assess established diseases. How-
ever, cohorts are likely to fail in the identification of early
multimorbid diseases, their causality and discovery of
biomarkers. Thus, the data of MeDALL are generalizable to
multimorbid NCDs across the life cycle. Funding from the
EU Structure and Cohesion Funds have been obtained by
the Region Languedoc Roussillon in the frame of MACVIA-
LR (76, 78) to maintain the database until new funding from
the EU or other sources is available for other projects.
Despite the successful experience of MeDALL to integrate
birth cohorts of asthma and allergy, we really do need to
escalate the level of integration. A new methodology should
be proposed to combine the strengths and weaknesses of the
birth cohorts, possibly enriching them with patient cohorts
(47, 86, 87), registered data in primary care (88), clinical trial
databases (89) and/or internet based studies. In very young
children, similar severe asthma phenotypes exist in patient
cohorts of persistent recurrent wheezers (86) and in cohorts
in the general population (90), suggesting the possibility of
pooling both types of cohorts. However, ethical issues are of
great importance in pooling such studies.
Developing a systems medicine approach to complex dis-
eases is a phenomenal challenge. MeDALL was used as a
model of systems medicine and has initiated a common lan-
guage for the assessment of all noncommunicable diseases
(91). The novel trend for the management of NCDs is evolving
towards integrative, holistic approaches. NCDs are intertwined
with ageing. To tackle NCDs in their totality in order to reduce
their burden and societal impact, it has been proposed that
NCDs should be considered as a single expression of disease
with different risk factors and entities. An innovative inte-
grated health system built around systems medicine and strate-
gic partnerships is proposed to combat NCDs (4, 91).
Acknowledgments
The authors would like to thank the members of the Scien-
tific and Ethics Advisory Boards who made invaluable com-
ments during the project duration: P Burney (Imperial
College, London, UK), SGO Johansson (Karolinska Insti-
tute, Stockholm, Sweden), J Kiley (NHLBI, Bethesda, USA),
P Sterk (Amsterdam University, NL), M Van Hague
(Karolinska Institute, Stockholm, Sweden), M Yazdanbakhsh
(Leiden University, NL), K Dierickx (Leuven, Belgium), T
Garani-Papadatos (Athens, Greece) and M Sutrop (Riga,
Estonia).
Conflicts of interest
The authors declare no conflict of interest.
References
1. Bousquet J, Anto J, Auffray C, Akdis M,
Cambon-Thomsen A, Keil T et al.
MeDALL (Mechanisms of the Development
of ALLergy): an integrated approach from
phenotypes to systems medicine. Allergy
2011;66:596–604.
2. Bousquet J, Anto JM, Wickman M, Keil T,
Valenta R, Haahtela T et al. Are allergic
multimorbidities and IgE polysensitization
associated with the persistence or re-occur-
rence of foetal type 2 signalling? The
MeDALL hypothesis Allergy 2015;70:1062–
1078.
3. Martinez FD. Genes, environments, develop-
ment and asthma: a reappraisal. Eur Respir
J 2007;29:179–184.
4. Bousquet J, Anto JM, Sterk PJ, Adcock IM,
Chung KF, Roca J et al. Systems medicine
and integrated care to combat chronic non-
communicable diseases. Genome Med
2011;3:43.
5. Anto JM, Pinart M, Akdis M, Auffray C,
Bachert C, Basagana X et al. Understanding
the complexity of IgE-related phenotypes
from childhood to young adulthood: a
Mechanisms of the Development of Allergy
(MeDALL) seminar. J Allergy Clin Immunol
2012;129:943–954.
6. Bousquet J, Gern JE, Martinez FD, Anto
JM, Johnson CC, Holt PG et al. Birth
cohorts in asthma and allergic diseases:
report of a NIAID/NHLBI/MeDALL joint
workshop. J Allergy Clin Immunol
2014;133:1535–1546.
7. Molter A, Simpson A, Berdel D, Brunekreef
B, Custovic A, Cyrys J et al. A multicentre
study of air pollution exposure and child-
hood asthma prevalence: the ESCAPE pro-
ject. Eur Respir J 2015;45:610–624.
8. Fuertes E, MacIntyre E, Agius R, Beelen R,
Brunekreef B, Bucci S et al. Associations
between particulate matter elements and
early-life pneumonia in seven birth cohorts:
results from the ESCAPE and TRANS-
PHORM projects. Int J Hyg Environ Health
2014;217:819–829.
9. Pedersen M, Giorgis-Allemand L, Bernard
C, Aguilera I, Andersen AM, Ballester F
et al. Ambient air pollution and low birth-
weight: a European cohort study
(ESCAPE). Lancet Respir Med 2013;1:695–
704.
10. Eeftens M, Beelen R, de Hoogh K, Bellan-
der T, Cesaroni G, Cirach M et al. Develop-
ment of land use regression models for PM
(2.5), PM(2.5) absorbance, PM(10) and PM
(coarse) in 20 European study areas; results
of the ESCAPE project. Environ Sci Technol
2012;46:11195–11205.
11. Hohmann C, Pinart M, Tischer C, Gehring
U, Heinrich J, Kull I et al. The development
of the MeDALL core questionnaires for a
harmonized follow-up assessment of eleven
European birth cohorts on asthma and aller-
gies. Int Arch Allergy Immunol
2014;163:215–224.
12. Bousquet J, Anto J, Sunyer J, Nieuwenhui-
jsen M, Vrijheid M, Keil T et al. Pooling
birth cohorts in allergy and asthma: Euro-
pean Union-funded initiatives–a MeDALL,
CHICOS, ENRIECO, and GA(2)LEN joint
paper. Int Arch Allergy Immunol 2013;161:1–
10.
13. Sucharew H, Ryan PH, Bernstein D, Succop
P, Khurana Hershey GK, Lockey J et al.
Exposure to traffic exhaust and night cough
during early childhood: the CCAAPS birth
cohort. Pediatr Allergy Immunol 2010;21(Pt
1):253–259.
14. Garcia Algar O, Pichini S, Basagana X, Puig
C, Vall O, Torrent M et al. Concentrations
and determinants of NO2 in homes of Ash-
ford, UK and Barcelona and Menorca,
Spain. Indoor Air 2004;14:298–304.
15. Wickman M, Kull I, Pershagen G, Nordvall
SL. The BAMSE project: presentation of a
prospective longitudinal birth cohort study.
Pediatr Allergy Immunol 2002;13(Suppl
15):11–13.
16. Wright J, Small N, Raynor P, Tuffnell D,
Bhopal R, Cameron N et al. Cohort profile:
the Born in Bradford multi-ethnic family
cohort study. Int J Epidemiol 2013;42:978–
991.
17. Raynor P. Born in Bradford, a cohort study
of babies born in Bradford, and their par-
Allergy 71 (2016) 1513–1525 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd.1522
MeDALL results and achievements Bousquet et al.
ents: protocol for the recruitment phase.
BMC Public Health 2008;8:327.
18. Host A, Halken S, Jacobsen HP, Christensen
AE, Herskind AM, Plesner K. Clinical course
of cow’s milk protein allergy/intolerance and
atopic diseases in childhood. Pediatr Allergy
Immunol 2002;13(Suppl 15):23–28.
19. Lodrup Carlsen KC. The environment and
childhood asthma (ECA) study in Oslo:
ECA-1 and ECA-2. Pediatr Allergy Immunol
2002;13(Suppl 15):29–31.
20. Slama R, Thiebaugeorges O, Goua V,
Aussel L, Sacco P, Bohet A et al. Maternal
personal exposure to airborne benzene and
intrauterine growth. Environ Health Perspect
2009;117:1313–1321.
21. Laubereau B, Brockow I, Zirngibl A, Kolet-
zko S, Gruebl A, von Berg A et al. Effect of
breast-feeding on the development of atopic
dermatitis during the first 3 years of life–re-
sults from the GINI-birth cohort study. J
Pediatr 2004;144:602–607.
22. Berg AV, Kramer U, Link E, Bollrath C,
Heinrich J, Brockow I et al. Impact of early
feeding on childhood eczema: development
after nutritional intervention compared with
the natural course–the GINIplus study up to
the age of 6 years. Clin Exp Allergy 2010;
40:627–636.
23. Aguilera I, Guxens M, Garcia-Esteban R,
Corbella T, Nieuwenhuijsen MJ, Foradada
CM et al. Association between GIS-based
exposure to urban air pollution during preg-
nancy and birth weight in the INMA Saba-
dell cohort. Environ Health Perspect
2009;117:1322–1327.
24. Heinrich J, Bolte G, Holscher B, Douwes J,
Lehmann I, Fahlbusch B et al. Allergens
and endotoxin on mothers’ mattresses and
total immunoglobulin E in cord blood of
neonates. Eur Respir J 2002;20:617–623.
25. Nickel R, Niggemann B, Gruber C, Kulig
M, Wahn U, Lau S. How should a birth
cohort study be organised? Experience from
the German MAS cohort study. Paediatr
Respir Rev 2002;3:169–176.
26. Illi S, von Mutius E, Lau S, Nickel R, Gru-
ber C, Niggemann B et al. The natural
course of atopic dermatitis from birth to age
7 years and the association with asthma. J
Allergy Clin Immunol 2004;113:925–931.
27. Nickel R, Illi S, Lau S, Sommerfeld C, Berg-
mann R, Kamin W et al. Variability of total
serum immunoglobulin E levels from birth
to the age of 10 years. A prospective evalua-
tion in a large birth cohort (German multi-
center allergy study). Clin Exp Allergy
2005;35:619–623.
28. Illi S, von Mutius E, Lau S, Niggemann B,
Gruber C, Wahn U. Perennial allergen sensi-
tisation early in life and chronic asthma in
children: a birth cohort study. Lancet
2006;368:763–770.
29. Clarisse B, Demattei C, Nikasinovic L, Just
J, Daures JP, Momas I. Bronchial obstruc-
tive phenotypes in the first year of life
among Paris birth cohort infants. Pediatr
Allergy Immunol 2009;20:126–133.
30. Wijga A, Smit HA, Brunekreef B, Gerritsen
J, Kerkhof M, Koopman LP et al. Are chil-
dren at high familial risk of developing
allergy born into a low risk environment?
The PIAMA birth cohort study. Prevention
and incidence of asthma and mite allergy.
Clin Exp Allergy 2001;31:576–581.
31. Chatzi L, Plana E, Daraki V, Karakosta P,
Alegkakis D, Tsatsanis C et al. Metabolic
syndrome in early pregnancy and risk of pre-
term birth. Am J Epidemiol 2009;170:829–
836.
32. Porta D, Forastiere F, Di Lallo D, Perucci
CA. Enrolment and follow-up of a birth
cohort in Rome. Epidemiol Prev
2007;31:303–308.
33. Maier D, Kalus W, Wolff M, Kalko SG,
Roca J, Marin de Mas I et al. Knowledge
management for systems biology a general
and visually driven framework applied to
translational medicine. BMC Syst Biol
2011;5:38.
34. Lupinek C, Wollmann E, Baar A, Banerjee
S, Breiteneder H, Broecker BM et al.
Advances in allergen-microarray technology
for diagnosis and monitoring of allergy: the
MeDALL allergen-chip. Methods
2014;66:106–119.
35. Skrindo I, Lupinek C, Valenta R, Hovland
V, Pahr S, Baar A et al. The use of the
MeDALL-chip to assess IgE sensitization: a
new diagnostic tool for allergic disease?
Pediatr Allergy Immunol 2015;26:239–246.
36. Westman M, Lupinek C, Bousquet J, Ander-
sson N, Pahr S, Baar A et al. Early child-
hood IgE reactivity to pathogenesis-related
class 10 proteins predicts allergic rhinitis in
adolescence. J Allergy Clin Immunol
2015;135:1199–1206.
37. Asarnoj A, Hamsten C, Waden K, Lupinek
C, Andersson N, Kull I et al. Sensitization
to cat and dog allergen molecules in child-
hood and prediction of symptoms of cat and
dog allergy in adolescence: a BAMSE/
MeDALL study. J Allergy Clin Immunol
2016;137:813–821.
38. Pinart M, Albang R, Maier D, Duran-Tau-
leria E, Mena G, Gimeno-Santos E et al.
Systematic review on the definition of aller-
gic diseases in children: the MeDALL
study. Int Arch Allergy Immunol
2015;168:110–121.
39. Belgrave DC, Buchan I, Bishop C, Lowe L,
Simpson A, Custovic A. Trajectories of lung
function during childhood. Am J Respir Crit
Care Med 2014;189:1101–1109.
40. Bousquet J, Van Cauwenberge P, Khaltaev
N. Allergic rhinitis and its impact on
asthma. J Allergy Clin Immunol 2001;108(5
Suppl):S147–S334.
41. Pinart M, Benet M, Annesi-Maesano I, von
Berg A, Berdel D, Carlsen KC et al. Comor-
bidity of eczema, rhinitis, and asthma in
IgE-sensitised and non-IgE-sensitised chil-
dren in MeDALL: a population-based
cohort study. Lancet Respir Med
2014;2:131–140.
42. Garcia-Aymerich J, Benet M, Saeys Y,
Pinart M, Basagana X, Smit HA et al.
Phenotyping asthma, rhinitis and eczema in
MeDALL population-based birth cohorts:
an allergic comorbidity cluster. Allergy
2015;70:973–984.
43. Bousquet J, Becker WM, Hejjaoui A, Cha-
nal I, Lebel B, Dhivert H et al. Differences
in clinical and immunologic reactivity of
patients allergic to grass pollens and to mul-
tiple-pollen species. II. Efficacy of a double-
blind, placebo-controlled, specific
immunotherapy with standardized extracts. J
Allergy Clin Immunol 1991;88:43–53.
44. Bousquet J, Hejjaoui A, Becker WM, Cour
P, Chanal I, Lebel B et al. Clinical and
immunologic reactivity of patients allergic to
grass pollens and to multiple pollen species.
I. Clinical and immunologic characteristics.
J Allergy Clin Immunol 1991;87:737–746.
45. Pene J, Rivier A, Lagier B, Becker WM,
Michel FB, Bousquet J. Differences in IL-4
release by PBMC are related with hetero-
geneity of atopy. Immunology 1994;81:58–
64.
46. Ballardini N, Bergstrom A, Wahlgren CF,
van Hage M, Hallner E, Kull I et al. IgE
antibodies in relation to prevalence and mul-
timorbidity of eczema, asthma, and rhinitis
from birth to adolescence. Allergy
2016;71:342–349.
47. Just J, Deslandes-Boutmy E, Amat F, Des-
seaux K, Nemni A, Bourrat E et al. Natural
history of allergic sensitization in infants
with early-onset atopic dermatitis: results
from ORCA study. Pediatr Allergy Immunol
2014;25:668–673.
48. Burte E, Bousquet J, Varraso R, Gormand
F, Just J, Matran R et al. Characterization
of rhinitis according to the asthma status in
adults using an unsupervised approach in
the EGEA study. PLoS One 2015;10:
e0136191.
49. Gehring UW, Hoek A, Bellander G, Berdel
T, Br€uske D, Fuertes I et al. Exposure to air
pollution and development of asthma and
rhinoconjunctivitis throughout childhood
and adolescence: a population-based birth
cohort study. Lancet Respir Med
2015;3:933–942.
50. Guerra S, Halonen M, Vasquez MM, Span-
genberg A, Stern DA, Morgan WJ et al.
Relation between circulating CC16 concen-
trations, lung function, and development of
Allergy 71 (2016) 1513–1525 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd. 1523
Bousquet et al. MeDALL results and achievements
chronic obstructive pulmonary disease across
the lifespan: a prospective study. Lancet
Respir Med 2015;3:613–620.
51. Coquet JM, Schuijs MJ, Smyth MJ, Des-
warte K, Beyaert R, Braun H et al. Inter-
leukin-21-producing CD4(+) T cells promote
type 2 immunity to house dust mites. Immu-
nity 2015;43:318–330.
52. Schuijs MJ, Willart MA, Vergote K, Gras
D, Deswarte K, Ege MJ et al. Farm dust
and endotoxin protect against allergy
through A20 induction in lung epithelial
cells. Science 2015;349:1106–1110.
53. Palomares O, Ruckert B, Jartti T, Kucuk-
sezer UC, Puhakka T, Gomez E et al.
Induction and maintenance of allergen-spe-
cific FOXP3+ Treg cells in human tonsils
as potential first-line organs of oral toler-
ance. J Allergy Clin Immunol 2012;129:510–
520.
54. Palomares O, Martin-Fontecha M, Lauener
R, Traidl-Hoffmann C, Cavkaytar O, Akdis
M et al. Regulatory T cells and immune reg-
ulation of allergic diseases: roles of IL-10
and TGF-beta. Genes Immun 2014;15:511–
520.
55. Kucuksezer UC, Palomares O, Ruckert B,
Jartti T, Puhakka T, Nandy A et al. Trigger-
ing of specific Toll-like receptors and proin-
flammatory cytokines breaks allergen-specific
T-cell tolerance in human tonsils and periph-
eral blood. J Allergy Clin Immunol
2013;131:875–885.
56. Stanic B, van de Veen W, Wirz OF, Ruckert
B, Morita H, Sollner S et al. IL-10-overex-
pressing B cells regulate innate and adaptive
immune responses. J Allergy Clin Immunol
2015;135:771–780.
57. van de Veen W, Stanic B, Yaman G,
Wawrzyniak M, Sollner S, Akdis DG et al.
IgG4 production is confined to human IL-
10-producing regulatory B cells that suppress
antigen-specific immune responses. J Allergy
Clin Immunol 2013;131:1204–1212.
58. Wegrzyn AS, Jakiela B, Ruckert B, Jutel M,
Akdis M, Sanak M et al. T-cell regulation
during viral and nonviral asthma exacerba-
tions. J Allergy Clin Immunol 2015;136:194–
197.
59. Wawrzyniak M, Ochsner U, Wirz O,
Wawrzyniak P, van de Veen W, Akdis CA
et al. A novel, dual cytokine-secretion assay
for the purification of human Th22 cells that
do not co-produce IL-17A. Allergy
2016;71:47–57.
60. Kast JI, Wanke K, Soyka MB, Wawrzyniak
P, Akdis D, Kingo K et al. The broad spec-
trum of interepithelial junctions in skin and
lung. J Allergy Clin Immunol 2012;130:544–
547.
61. Soyka MB, Holzmann D, Akdis CA. Regu-
latory cells in allergen-specific immunother-
apy. Immunotherapy 2012;4:389–396.
62. Kubo T, Wawrzyniak P, Morita H, Sugita
K, Wanke K, Kast JI et al. CpG-DNA
enhances the tight junction integrity of the
bronchial epithelial cell barrier. J Allergy
Clin Immunol 2015;136:1413–1416.
63. Smit HA, Pinart M, Anto JM, Keil T, Bous-
quet J, Carlsen KH et al. Childhood asthma
prediction models: a systematic review. Lan-
cet Respir Med 2015;3:973–984.
64. Bousquet PJ, Devillier P, Tadmouri A, Mes-
bah K, Demoly P, Bousquet J. Clinical rele-
vance of cluster analysis in phenotyping
allergic rhinitis in a real-life study. Int Arch
Allergy Immunol 2015;166:231–240.
65. Canonica GW, Bachert C, Hellings P, Ryan
D, Valovirta E, Wickman M et al. Allergen
immunotherapy (AIT): a prototype of preci-
sion medicine. World Allergy Organ J
2015;8:31.
66. Bousquet J, Burney PG, Zuberbier T,
Cauwenberge PV, Akdis CA, Bindslev-Jen-
sen C et al. GA2 LEN (Global Allergy and
Asthma European Network) addresses the
allergy and asthma ‘epidemic’. Allergy
2009;64:969–977.
67. Kauffmann F, Cambon-Thomsen A. Tracing
biological collections: between books and
clinical trials. JAMA 2008;299:2316–2318.
68. Anastasova V, Mahalatchimy A, Rial-Seb-
bag E, Anto Boque JM, Keil T, Sunyer J
et al. Communication of results and disclo-
sure of incidental findings in longitudinal
paediatric research. Pediatr Allergy Immunol
2013;24:389–394.
69. Bousquet J, Kiley J, Bateman ED, Viegi G,
Cruz AA, Khaltaev N et al. Prioritised
research agenda for prevention and control
of chronic respiratory diseases. Eur Respir J
2010;36:995–1001.
70. Bousquet J, Dahl R, Khaltaev N. Global
alliance against chronic respiratory diseases.
Allergy 2007;62:216–223.
71. Bousquet J, Khaltaev N. Global Surveil-
lance, Prevention and Control of Chronic
Respiratory Diseases. A Comprehensive
Approach. Global Alliance Against Chronic
Respiratory Diseases. Geneva, Switzerland:
World Health Organization, 2007: 148
pages. ISBN 978 92 4 156346 8.
72. Bousquet J, Mantzouranis E, Cruz AA, Ait-
Khaled N, Baena-Cagnani CE, Bleecker ER
et al. Uniform definition of asthma severity,
control, and exacerbations: document pre-
sented for the World Health Organization
consultation on severe asthma. J Allergy
Clin Immunol 2010;126:926–938.
73. Bousquet J, Addis A, Adcock I, Agache I,
Agusti A, Alonso A et al. Integrated care
pathways for airway diseases (AIRWAYS-
ICPs). Eur Respir J 2014;44:304–323.
74. Bousquet J, Barbara C, Bateman E, Bel E,
Bewick M, Chavannes N et al. AIRWAYS
ICPs (European Innovation Partnership on
Active and Healthy Ageing) from concept to
implementation. Eur Respir J 2016;47:1028–
1033.
75. Bousquet J, Schunemann HJ, Fonseca J,
Samolinski B, Bachert C, Canonica GW
et al. MACVIA-ARIA Sentinel NetworK
for allergic rhinitis (MASK-rhinitis): the new
generation guideline implementation. Allergy
2015;70:1372–1392.
76. Bousquet J, Bourquin C, Auge P, Domy P,
Bringer J, Camuzat T et al. MACVIA-LR
reference site of the European innovation
partnership on active and healthy ageing.
Eur GeriatrMed 2014;5:406–415.
77. Bousquet J, Michel J, Standberg T, Crooks
G, Iakovidis I, Gomez M. The European
innovation partnership on active and healthy
ageing: the European geriatric medicine
introduces the EIP on AHA column. Eur
Geriatr Med 2014;5:361–362.
78. Bousquet J, Mercier J, Avignon A, Bourret
R, Camuzat T. MACVIA-LR (France) case
study. Report EUR 27150 EN. In: Abadie
F, editor. Strategic Intelligence Monitor on
Personal Health Systems Phase 3
(SIMPHS3). JRC94487. Luxembourg:
Publications Office of the European Union:
JRC (Joint Research Centre) Science and
Policy Report, 2015: https://ec.europa.eu/jrc.
79. Samolinski B, Fronczak A, Kuna P, Akdis
CA, Anto JM, Bialoszewski AZ et al.
Prevention and control of childhood asthma
and allergy in the EU from the public health
point of view: Polish Presidency of the Euro-
pean Union. Allergy 2012;67:726–731.
80. Samolinski B, Fronczak A, Wlodarczyk A,
Bousquet J. Council of the European Union
conclusions on chronic respiratory diseases
in children. Lancet 2012;379:e45–e46.
81. Bousquet J, Tanasescu CC, Camuzat T,
Anto JM, Blasi F, Neou A et al. Impact of
early diagnosis and control of chronic respi-
ratory diseases on active and healthy ageing.
A debate at the European Union parliament.
Allergy 2013;68:555–561.
82. Bousquet J, Anto JM, Berkouk K, Gergen
P, Antunes JP, Auge P et al. Developmental
determinants in non-communicable chronic
diseases and ageing. Thorax 2015;70:595–
597.
83. Samolinski B, Raciborski F, Bousquet J,
Kosiniak-Kamysz W, Radziewicz-Winnicki
I, Kłak A et al. Development of senioral
policy in Poland. Eur Geriatr Med
2015;6:389–395.
84. Haahtela T, von Hertzen L, Makela M,
Hannuksela M. Finnish allergy programme
2008–2018–time to act and change the
course. Allergy 2008;63:634–645.
85. Lodrup Carlsen KC, Haahtela T, Carlsen
KH, Smith A, Bjerke M, Wickman M et al.
Integrated allergy and asthma prevention
and care: report of the MeDALL/AIR-
Allergy 71 (2016) 1513–1525 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd.1524
MeDALL results and achievements Bousquet et al.
WAYS ICPs meeting at the Ministry of
Health and Care Services, Oslo, Norway. Int
Arch Allergy Immunol 2015;167:57–64.
86. Just J, Gouvis-Echraghi R, Couderc R,
Guillemot-Lambert N, Saint-Pierre P. Novel
severe wheezy young children phenotypes:
boys atopic multiple-trigger and girls nona-
topic uncontrolled wheeze. J Allergy Clin
Immunol 2012;130:103–110.
87. Just J, Gouvis-Echraghi R, Rouve S, Wanin
S, Moreau D, Annesi-Maesano I. Two nov-
el, severe asthma phenotypes identified dur-
ing childhood using a clustering approach.
Eur Respir J 2012;40:55–60.
88. Price DB, Rigazio A, Campbell JD, Bleecker
ER, Corrigan CJ, Thomas M et al. Blood
eosinophil count and prospective annual
asthma disease burden: a UK cohort study.
Lancet Respir Med 2015;3:849–858.
89. Angus DC. Fusing randomized trials with
big data: the key to self-learning health care
systems? JAMA 2015;314:767–768.
90. Herr M, Just J, Nikasinovic L, Foucault
C, Le Marec AM, Giordanella JP et al.
Risk factors and characteristics of respira-
tory and allergic phenotypes in early
childhood. J Allergy Clin Immunol
2012;130:389–396.
91. Bousquet J, Jorgensen C, Dauzat M, Cesar-
io A, Camuzat T, Bourret R et al. Systems
medicine approaches for the definition of
complex phenotypes in chronic diseases and
ageing. From concept to implementation
and policies. Curr Pharm Des 2014;20:5928–
5944.
92. Gough H, Grabenhenrich L, Reich A, Eck-
ers N, Nitsche O, Schramm D et al. Allergic
multimorbidity of asthma, rhinitis, and
eczema over 20 years in the German birth
cohort MAS. Pediatr Allergy Immunol
2015;26:431–437.
93. Bousquet J, Anto JM, Bachert C, Bousquet
PJ, Colombo P, Crameri R et al. Factors
responsible for differences between asymp-
tomatic subjects and patients presenting an
IgE sensitization to allergens. A GALEN
project. Allergy 2006;61:671–680.
94. Amaral AF, Minelli C, Guerra S, Wjst M,
Probst-Hensch N, Pin I et al. The locus
C11orf30 increases susceptibility to poly-sen-
sitization. Allergy 2015;70:328–333.
95. Ferreira MA, Matheson MC, Tang CS,
Granell R, Ang W, Hui J et al. Genome-
wide association analysis identifies 11 risk
variants associated with the asthma with hay
fever phenotype. J Allergy Clin Immunol
2014;133:1564–1571.
Allergy 71 (2016) 1513–1525 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd. 1525
Bousquet et al. MeDALL results and achievements
